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INTRODUCTION . 
Brachial plexus nerve block . is a regional anaesthesia technique which is  
developing  in the day to . day anaesthesia . practice. It is sometimes used as an  
alternative to or along with general anaesthesia for upper extremity surgeries.  It  
is a safer alternative  . to general anaesthesia  . for upper limb surgery and also  
works excellently in relieving . po .st o.perative pain and  .  also . proving excellent  .  
hemodynamic stability . . . Its becoming .  increasing .ly popular because the field of  
regional anaesthesia has improved  over time.  Several newer  . adjuvant drugs  
and many  . advanced techniques like ultrasound /peripheral .  nerve stimulator for  
successful .  and safe block. The main  .  advantages are it avoids .  the adverse  
effects of  . general  anaesthesia. It creates less financial burden to the patient  .   
and hospital stay is lessened. 
         Many adjuvants to local anaesthetics  .  like clonidine, dexmeditomidine,  
Nalbuphine,  buprenorphine, .  dexamethasone etc have been developed  .  to  
increase the quality of the  . nerve block  as well as .  hastening the onset of  
blockade and increasing .  the duration of blockade. Nalbuphine is a  
novel drug classified under opioid agonist- antagonist and it is now being 
increasingly used as an  adjuvant in brachial plexus nerve blocks. It acts as an 
antagonist at mu-receptors and agonist at  kappa receptors, to provide 
reasonably potent and adequate analgesia. Also,there is no supportive  
documentary evidence of neurotoxicity following the use of Nalbuphine in  
peripheral nerve blocks.  
In human beings, Nalbuphine is usually added to local anaesthetics while  
performing peripheral nerve blocks. This  has been proved to increase the  
duration of post  operative analgesia.  
Bupivacaine is a local anaesthetic  being used commonly in practice for giving  
peripheral nerve blocks. The aim of this studysis   to try to prove  . the efficacy 
of  Nalbuphine . , when it is added  as an  adjuvant to . Bupivacaine while  
performing . supraclavicular brachial plexus  . nerve blocks. 
 
AIMS  . AND OBJECTIVES OF  . THE STUDY 
 
        The aim and objective . of the study is to prove . the efficacy of 
 Nalbuphine when it is addedn as an adjuvant to . Bupivacaine  while performing  
supraclavicular  . brachial plexus blocks. This is done  by observing and assessing   
the 
1. Time to the Onset  .of  the sensory block 
2. Time to the onset of  the motor block 
3. How long is the duration of motor block? 
4. How long is the duration of sensory block 
  .    3. Quality . of . anaesthesia 
5. Time of request of first rescue analgesic (which indicates the duration of 
post operative analgesia) 
  
 
                           ANATOMY OF BRACHIAL PLEXUS 
 
     To perform a successful brachial plexus blockade, we must be thorough  
about the detailed anatomy of the brachial . plexus and its  
distribution. An in-depth  knowlwdge on . the  muscular, vascular  . and  the  
fascial relationship of the brachial  plexus  . beginning from its formation  . and  
distribution is needed. This only helps us in successfully  performing  . . the  
various techniques of  brachial plexus block  at the  . various levels. 
 
The brachial plexus  . gives innervation to the upper limb  .. it is constituted by  
Roots ,Trunks, Cords And divisions. 
  
The major contribution to brachial plexus comes from the ventral ramus  
of C5  to C8 and T1 nerves.  
T2 below and . C4 nerve also contributes to form the brachial plexus. 
The roots join to form the trunks, that lies above the clavicle. 
 The brachial plexus nerves are very much compacted  . at the level of 
 supraclavicular area. It travels through the . fascia enclosed space . which  
lies between the scalenus  . medius and scalenus anterior  . muscle. 
At this level , the  brachial plexus is  . accompanied by the subclavian  
artery. There it enters the fascia  . that lies over the muscle. They together   
forms the neurovascular bundle. This fascia continues as  .   
the axillary sheath . in the axilla. 
            RELATIONS OF THE BRACHIAL PLEXUS 
 
ANTERIOR RELATIONS 
The skin, . the superficial fascia,  . platysma, supraclavicular  . branches of the 
superficial . cervical plexus, the deep  . fascia and the external .  jugular  
vein.Anterior to the upper part lies the scalenus anterior.   . the clavicle lies inthe  
lower part. 
POSTERIOR RELATIONS 
Scalenus . medius muscle, the long . thoracic nerve of Bell 
INFERIOR RELATIONS 
Inferiorly, the plexus is related to the fourth rib 
 
SUPERIOR RELATIONS 
Initially the brachial plexus lies  above and then it. is lateral . to the  
subclavian artery. 
             FORMATION OF THE BRACHIAL PLEXUS 
 
               The upper trunk is  .  formed by C5 to . C6. The middle trunk is formed  
by C7 . . The inferior trunk is contributed by C8-T1. Before it enters  . the axilla,  
the plexus goes down to lie . between the clavicle  . and the first rib at  . the level of  
the anterior scalene  muscle.  
The trunks are compacted  . over the first rib, just posterior to the  
subclavian artery. Each trunk splits to form anterior and posterior divisions. A  
total of 6 divisions are formed., these six divisions regroups  to form . lateral,  
medial . and posterior cords  . below the clavicle. At this level They are . related to  
the axillary artery .  
The  . subclavian artery continues  . as the axillary artery . Lateral  
cord is . formed . by the anterior divisions  . of the middle and the superior trunks.  
Medial cord is formed  . by the anterior division . . of inferior trunk. Posterior  
divisions of superior, middle and inferior trunks form the posterior cord.At the  
lateral margin of pectoralis minor,  Every cord gives  off a large branch, . before  
ending as a . terminal nerve. 
Lateral cord forms  . the lateral branch of  . median nerve. the cord terminates as  
the musculocutaneous .  nerve. 
Medial cord forms  . the medial branch of  .  median nerve .  it terminates  . to form  
the ulnar nerve. The posterior cord . forms the axillary nerve  .  and terminates as  
the radial nerve. 
 Before entering the axilla, the musculocutaneous nerve  leaves .  the sheath .  
then it lies in .  the coracobrachialis muscle. 
 
Thus the brachial plexus nerve  .  blocks can be .  performed .  at various levels ie;  
the level of roots, trunks, .  cords, or at the level of   peripheral branches .   
Brachial plexus block at each level possess its own merits as well as demerits. 
 
  
 
 
 
SUPRACLAVICULAR .  BRACHIAL PLEXUS BLOCK  .  
        
             The  Supraclavicular brachial plexus block is otherwise known as the  
spinal of the arm. 
 
HISTORY 
     The history dates back to 1884. William Steward .  Halsted performed the  
first brachial plexus block.   
Crile performed the supraclavicular block in 1887. 
 In 1911,Hulenkampff  .  explained the percutaneous technique of  .  brachial  
plexus block by .  supraclavicularApproach. 
Hirshel described  .  the brachial plexus block .  via axillary nerve in 1911 
 F. Paul .  Ansbro  described  the concept of continuous brachial .  block technique  
in 1946. 
                 Many approaches are .  being developed since the beginning .  to block 
 the  brachial plexus. Newer approaches  .  tend to reduce the complications  .  as  
well as the  failiure  .  rate of the procedure. 
The most commonly .  used  approaches are 
1. The classical . technique By Patrician 
2. Brown’s Vertical .  plumb bob method .  
3. Bonica and Moore explained the First .  rib walkover technique  .  
4. Subclavian .  perivascular technique (Winnie&Collins ) 
5. Parascalene  approach .  ( Vongvises and Panijayanond) .  in 1979. 
6. Infraclavicular  brachial .  plexus approach using peripheral .  nerve 
stimulator 
1. CLASSICAL SUPRACLAVICULAR .  BLOCK OF HULENKAMPFF 
 
First, infiltrate the puncture site  with local anaesthetic. The needle is  
 
.inserted 1cm above the .  midpoint of the clavicle. The needle is inserted  
 
in such a waythet it is  parallel .  to the long axis of patient  .  head and neck.  
 
The rib is reached at  depth .  of 3 to 4 cm . the needle .  is then  walked off  
 
over the  first  .  rib until the elicitation of paraesthesia . Inject the local  
 
\anaesthetic .  solution  
 
after careful negative .  aspiration of blood to .  rule out inadvertent 
intravascular injection. 
 
2. SUBCLAVIAN PERIVASCULAR .  APPROACH OF WINNIE  .  AND 
COLLINS 
               Identify the interscalene  .  groove just posterior to  .  the subclavian 
artery .  . Insert the needle .  just posterior and superior to .  the subclavian  
 
             artery pulsation .   then direct the needle  caudally .  at a flat angle 
             against .  the skin. Inject the local anaesthetic after elicitation of 
paraesthesia. 
 
3. Plumb BOB SUPRACLAVICULAR BLOCK 
 
The trunks .  of the brachial plexus lies  .  cephalic and posterior to .  the  
 
subclavian artery .  at the level of the first rib. Turn the patient’s head 
 
to an angle of 30 degrees to .  the contralateral  side. Direct the needle in a 
perpendicular fashion at the  lateral border  .  of the  
 
sternocleidomastoid muscle and  immiediately .  above the clavicle. After 
eliciting paraesthesia, local .   
 
anaesthetic is injected  .  after confirming negative aspiration  .  of blood 
 
COMPLICATIONS .  
 
• Pneumothorax .  
 
• Horners .  syndrome 
 
• Paralysis of  Ipsilateral .  phrenic nerve .  
 
• Paralysis of  the Recurrent laryngeal .  nerve 
 
• Haemothorax 
 
• Puncture and injury to the Subclavian artery  
 
 
ULTRASONOGRAPHY 
 
 
 
         Ultrasound are high frequency .  sound waves over 20000 .  cycles per  
second(20 KHz). These waves  .  are used for scanning .  various tissues of human  .   
body , inaudible to humans  .  and can be transmitted .  as beams. 
 
PRINCIPLES OF ULTRASONOGRAPHY 
Ultrasound works on the principle known as Piezoelectric effect. The  
piezoelectric .  crystals are arranged in the transducer. They have  .  the property of 
changing the shape on application of electrical voltage . they  convert  .  electrical 
energy into sound energy, when electrical  voltage is applied to them. The 
intensity of the sound  
waves .  can be either inhibited .  or amplified. 
           The rate of absorption .  of sound waves is  .  highest in solid structures  .  
and it is least in liquids. The  reflected .  waves enter the transducer. They strike .  
the  
piezoelectric crystals  . .  Thus,  it converts sound energy .  to electrical energy. 
The  
reflectivity .  of the object is . computed from the . amplitude of the  
reflected . sound. 
            
The difference in the acoustic  .  impedence among the tissues  .  forming the 
interface determines the proportion of sound reflected or transmitted.  
The acoustic impedance  .  is measured in the Rayls unit. It is the product of 
velocity .  and  
density of the tissue in which  .  it propagates sound. Bone and air have .   
different impedance when .  compared to other tissues. Therefore,  majority of 
sound is  
reflected. Hence, ultrasound .  cannot be used to image structures which are  .  
deep to bone or air. 
       Low frequency . transducers( 2 to 8 MHz) have poor  .  resolving power. But 
they have higher penetration.  
penetration. High frequency .  transducers ( 10 to 20 MHz) produce higher  .   
resolution . They produce clear view . for the superficial structures.  They  
cannot penetrate  further  .  into the tissue. 
COMPONENTS OF ULTRASOUND 
1. TRANSDUCER .  
2. RECEIVER AND .  PROCESSOR 
3. IMAGE AND .  DISPLAY 
TRANSDUCER 
        The transducer can convert   mechanical energy into electrical .  energy and 
vice  
versa. It possess the ability to receive the echoes which are reflected. 
RECEIVER AND PROCESSOR 
 The scattered energy is detected and amplified  .  They adjust  the signals for 
providing display. 
IMAGE DISPLAY 
It shows the received ultrasound waves in various modes. The various modes  
In use are: 
A mode: 
       Amplitude .  modulation. It shows the voltage developed .   
across the transducer and  .  is shown  as a vertical deflection .  on the face of  
the oscilloscope. The strength  .  and position of a reflecting .  structure can only 
be  
recorded. 
M .  Mode: 
   It is also known .  as Motion modulation. It displays echo amplitude  . . It shows  
the position .  of  moving reflections. It is  .  employed  for evaluation of  
Chambers of the heart, heart valves  and the walls of the vessels. 
B Mode: 
   It is also known .  as  . Brightness modulation. It uses  multiple .  ultrasound 
pulses and  generates  a two .  dimensional image. 
ULTRASOUND IN ANAESTHESIA 
In anasesthesia, ultrasound . is employed : 
1. For obtaining.  intravascular access 
2. regional anaesthesia 
3. Transesophageal echocardiography 
PERIPHERAL NERVE BLOCK 
 
A successful regional block needs a  better and precise distribution of local 
anaesthetic  
solution around the  nerve and the nerve plexus. Ultrasound imaging has the  
following advantages. 
- Directly.  Visualise the  nerve structures . 
- Directly visualise the  related structures like tendons .  and blood vessels. 
- Better guidance of needle. 
- Better monitoring of the .  drug spread 
- Less incidence of .  intraneuronal and intravascular .  puncture 
- Can reposition.   The  needle if needed 
- Can be used in.  patients with  low  response.  to nerve stimulation 
The nerves appear .  as “honeycomb appearance” on high.  resolution  
ultrasonography. They appear .  as hyperechoic fascicles which .  are 
 surrounded by hyperechoic . tissues. Different blocks are performed.  with  
different frequencies. 
The brachial plexus is.  blocked at the interscalene .  and the 
supraclavicular  
levels.  by  10 to 15 MHz probe. 
The sciatic, popliteal.  and infraclavicular block is .  performed with 4 to 8  
MHz.  probe. 
     To perform an ultrasound.  guided nerve block, the entire .  anatomical  
structures need to be  visualised.  in the field. To achieve this, 
optimisation  
of frequencies, positioning.  of the focal zones and the depth of 
penetration  
is necessary. Place the needle appropriately and then administer the local  
anaesthetic solution. The  spread of the drug is visualised  
sonographically. Bicarbonate containing solution is better  
avoided since it interferes with the imaging due to its carbondioxide  
production. 
NEEDLE APPROACH: 
      There are 2 ways of inserting the needle. They are in plane(parallel)  
and out of plane(not  parallel) to the ultrasound waves. In the in plane  
technique, the needle entry is from the side of the probe, whereas the  
needle entry is away from the probe in out of plane technique.  
The entire needle shaft is seen in the in plane technique whereas, only the 
 needle tip is visualised in the out plane approach. 
 
 
 
ERGONOMICS: 
    The operator stands on the same side, where the nerve is to be blocked.  
Position the ultrasound machine on the opposite side. Hold the needle with the  
dominant hand and the probe is held with the non dominant hand. Place the   
monitor in the front of the operator in such a way that he is able  
to visualise the entire screen without any kind of physical strain. 
PROBE ORIENTATION: 
    A marker is present on one end of the transducer probe. The operator needs to .   
be oriented.   about the marker. This avoids. confusion, in case of manipulation . .   
of the probe. 
 
                             BUPIVACAINE 
                            
   Bupivacaine is a member of the pipecoloxylidide member of amide local  
anaesthetics. They  possess the property of chirality as they  have an assymetric  
carbon atom. Hence, Bupivacaine has a  left and right sided configuration. It  is  
while, odourless, soluble in water and 95% ethanol, and less  
soluble in chloroform or acetone 
CHEMICAL STRUCTURE: 
 
 
   Solution of  Bupivacaine hydrochloride is clear and colourless. It is used for  
peripheral nerve blocks, local infiltrations, epidural and caudal blocks.  
Bupivacaine hydrochloride injection solution can be autoclaved. 
      Bupivacaine is a member of aminoacyl group of local anaesthetics. It is a  
homologue of mepivacaine and is chemically related to lignocaine. All these 3  
local anaesthetics possess an amide  linkage btween the aromatic nucleus and  
the amino or piperidine group. These tHRee differ in this  
respect from the procaine type of local anaesthetics, which possess an ester  
linkage. 
        It is available in 4ml ampoules where each ml contains 5 mg of hyperbaric  
Bupivacaine  hydrochloride. 
   It is also available in 15 ml vials , where each ml contains 5mg anhydrous  
Bupivacaine  Hydrochloride.   
CLINICAL PHARMACOLOGY: 
                       Bupivacaine acts  by binding to the intracellular portion of the  
voltage gated sodium channels , thereby.  blocking the sodium ion influx.  into 
the 
 nerve cells, which prevents.  depolarisation. 
It blocks the generation.  and conduction of.  nerve impulses by: 
1. Amplifying the threshold.  for electrical excitation .  in the nerve 
2. Decreasing the speed  of  the propogation.  of the impulse through the 
nerve 
3. Decreasing the rate.  of rise of the action potential 
Compared  to the other local anaesthetics, Bupivacaine is highly cardiotoxic.  
At low therapeutic  doses, Bupivacaine does not cause much cardiovascular  
changes or changes cardiac contractility or conduction.  But, toxic blood  
concentrations of Bupivacaine can result in major abnormalities  
in cardiac conduction and excitability, which in turn leads to major 
 ventricular arrythmias, atrioventricular blocks and bradycardia. Depression 
of myocardial  contractility leads to decreased cardiac output and arterial  
blood pressure leading to cardiac arrest and death. But, these changes have 
 been reported mostly due to inadvertent intravascular injection of  
Bupivacaine. But, its racemic mixture, S- enantiomer is relatively less  
cardiotoxic. 
Adverse effects on the central nervous system include circumoral numbness,  
facial tingling, vertigo, tinnitus, tremors and convulsions. 
PHARMACOKINETICS: 
               The rate of absorption of bupivacaine is dependent on its route of  
administration, site of administration, total dose, and concentration of the  
drug administered and the presence or absence of epinepH.Rine in the 
solution.  
EpinepH.Rine in concentrations of 1:200000 in the anaesthetic solution  
prolongs the duration of action and permits usage of larger total doses by  
reducing the rate of absorption and peak plasma concentratiion of  
bupivacaine. 
       Certain clinical studies have found that the peak plasma concentrations,  
maximum spread of  analgesia, and motor blockade produced by  
Bupivacaine is found in elderly when compared to young subjects. 
1. The duration of anaesthesia is about 240 to 480 mins 
2. Half life of the drug is 210 minutes 
3. The Maximum single dose for infiltration is 175 mg 
4. Toxic plasma concentration is  more than 3 microgram/dl 
5. pKa: 8.1 
6. the drug is 95% bound to plasma proteins 
7. fraction of unionised bupiacaine at pH7.4 is 17% and pH 7.6 is 24 %. 
8. Volume of distribution is 73 L 
9. Clearence : 0.47 L/min. The total plasma clearence is decreased in elderly 
patients 
 The rate and degree of diffusion of  any local anaesthetic is dependent on: 
1. Plasma protein binding capacity of the drug 
2. Degree of ionisation of the drug 
3. The lipid solubility of the drug 
The fetal to maternal circulation of local anaesthetics is inversely  
 
proportional to their plasma protein binding capacity. Hence, only the  
 
unbound or free fraction of the drug in the maternal circulation is  
 
available for placental transfer.  The plasma protein binding capacity  
 
of bupivacaine is 0.9%. hence, the ration of fetal umbilical vein to 
 
               maternal arterial concentration of Bupivacaine is only 32 %. 
 
Likewise, lipid soluble or water soluble drugs which occur in non  
 
ionised form in the circulation readily crosses maternal circulation to  
 
enter the fetal circulation, whereas the water soluble or ionised drugs  
 
do not readily cross the placental barrier. The lungs are   
 
also capable of extracting bupivacaine from the circulation. 
 
Possible pathways of Bupivacaine metabolism include  
 
Aromatichydroxylation, N- dealkylation, amide hydrolysis,  
 
and conjugation. Alpha acid glycoprotein is the most  
 
important plasma  protein binding site of Bupivacaine. The major  
 
metabolite of  Bupivacaine is Pipecoloxylidide, which is mainly  
 catalysed by cytocH.Rome p450 3A4.   
 
Pipecoloxylidide is then further hydroxylated to form glucuronide  
conjugates. 
 
The kidney is  the major excretory organ  for most of the local  
 
anaesthetics and their  metabolites. Urinary excretion is affected by  
 
the urinary perfusion and factors affecting the urinary ph . 
 
 
                        NALBUPHINE 
 
Nalbuphine hydrochloride is a synthetic opioid agonist- antagonist analgesic. It 
belongs to 
Phenantherene series.  Chemically, it is  related  to the widely used opioid  
antagonist naloxone and the potent  opioid agonist cymorphone. Chemically,  
Nalbuphine hydrochloride is 17-cyclobutylmethyl 4, alpha epoxy morphinan-  
3,6 alpha 14 triol hydrochloride. 
The molecular weight of Nalbuphine hydrochloride is 393.91 . it is soluble in  
water(35.mg/ml at 2 degrees) and ethanol (0.8%) and is insoluble in CHCl3 and  
ether. Nalbuphine hydrochloride has pKa values of 8.71 and 9.96. the molecular  
formula is C21H27NO4 HCl. 
 
COMPOSITION: 
 Each ml contains clear, odourless solution of Nalbuphine hydrochloride  
dihydrate equivalent to anhydrous Nalbuphine hydrochloride 10mg/20mg. 
The structural formula is 
 
PROPERTIES: 
• It binds to mu as well as kappa and delta opioid receptors. 
• Nalbuphine acts as an antagonist at mu receptors ans ad an agoinist at 
kappa receptors. 
• Activation of supraspinal and spinal kappa receptors results in linited 
analgesia, respiratory depression and sedation. 
• In rats, administration of Nalbuphine with morphine dose dependently 
blocked the development of  morphine tolerance without attenuation of 
the antinociceptive effect of morphine. 
• It is equally potent asan analgesic to morphine. Nalbuphine has no 
euphoriant effects. 
• It is about one fourth as potent as morphine as an antagonist. 
• Naloxone reverses the agoist effects of Nalbuphine 
• Nalbuphine 10 mg im produces analgesia with an onset of effect and 
duration of action is simillar to that of morphine. 
• Depression of ventilation is similar to morphine. But it shows a ceiling 
effect at the dose of 0.5 mg/kg.it antagonises the respiratory depressant 
effects of co administered pure mu opioid agonists, but the analgesic 
effect is additive in nature. 
• The incidence of dysphoria is less in comparison to butorphanol and 
pentazocine 
• In contrast to pentazocine, Nalbuphine does not increase systemic blood 
pressure, pulmonary artery blood pressure, heart rate or atrial filling 
pressures. 
• Withdrawal symptoms are milder compared to that of morphine, but 
similar to that produced by pentazocine. 
• Abuse potential is low 
• Nalbuphine causes lesser incidence of gastrointestinal side effects when 
compared  to other opioids 
• The antagoinist effects of Nalbuphine occurs due to its action on mu 
receptors. This could be an advantage in the post operative period to 
reverse the ventilatory depressant effects of opioid agonists, while still 
maintaining the analgesia. 
• Onset of action is rapid within  5 to 10 mins 
• Duration of action is long 3 to 6 hours 
• Plasma elimination half life is  hours 
PHARMACOKINETICS 
          
 Absorption: 
     The bio availability by oral route is 12 to 17 % due to a significant first pass  
 metabolism. The bioavailability is about 80 % by the  intramuscular and  
 
subcutaneous routes. 
 
Distribution: 
 
 Nalbuphine is 25 to 40 % plasma protein bound. The volume of distribution is  
 
162- 498 litres. 
 
Metabolism: 
  
It is metabolised predominantly in the liver to two inactive conjugates which are  
 
secreted in to the bile. 
 
Excretion: 
 
 The metabolites of Nalbuphine are excreted mainly in the faeces. A small  
 
fraction is excreted in the urine. The clearence is 0.8 to 2.3 liter per minute.  
 
Elimination half life is 110 to 160 minutes. 
 
Side effects: 
  
Sedation, dizziness, vertigo, dry mouth, headache. Nalbuphine cause less nausea  
 
and vomiting.  
 
Psychomimetic effects and dependence are less as compared to morphine. 
 
 
ULTRASOUND GUIDED SUPRACLAVICULAR NERVE BLOCK: 
Place the patient  in a supine . position .  Turn the patient’s head to  30. degree  
towards. the. opposite side. Place a linear .. high frequency probe.  over the  
supraclavicular .  fossa.  Just above . the clavicle.  Angulate the probe slightly  
. towards the thorax . Identify the subclavian artery.  by  
its.  visible pulsation. Just above and lateral to the subclavian artery, 
 multiple hyperechoic. Disks are seen. This confirm the brachial plexus.  
The first rib is visualised as a Hyperechoic line. just deep to the artery. Identify 
the pleura, adjacent to the rib. It is differentiated.  from bone by 
  its movement .  with respiration. 
 
To perform,  an out .  of plane technique,a 22.  gauge short tip, blunted .  tip needle 
is used.  
The skin is first .  anaesthetised with 1-2 ml.  of lignocaine. Then, the needle is .   
introduced . just  above to.  the ultrasound probe in a posterior and .  caudal  
fashion. Inject about 30.  ml of local anaesthetic.  solution,  
after careful aspiration .  to rule out an accidental.  and inadvertent intravascular 
 injection. The spread of .  the drug around.  the brachial plexus is visualised. 
       For an in plane.  technique, a longer needle is required. The skin is first .   
anaesthetised. Introduce the needle just lateral to the ultrasound beam. The  
needle.  is then.  advanced through.  the  subclavian artery medially, until.  the tip 
is  
visualised.  near the brachial plexus, just lateral and superficial to the  
subclavia.n artery. Inject 30 ml.  of local anaesthetic solution.  after careful 
aspiration to.  rule out intravascular injection. 
  
 
REVIEW OF LITERATURE: 
 
Mohammed et al  conducted a study on the effect of .  Nalbuphine as an 
adjuvant . 
 
with Bupivacaine.  in supraclavicular brachial.  plexus blocks.   
 
The test group(Nalbuphine)  revealed a greater increase in.  the duration of 
motor block.,  
 
while comparing  with the.  control group. Significant .  increase  was also shown 
in  
 
the duration.  of sensory block in Test(Nalbuphine) .  group, when compared to 
control.   
 
Group. The onset time of blockade was unaffected in both the groups.  
 
An increase was noted.  in the duration of  analgesia in the Test group. 
 
 
Cenklham et al conducted a study on the effectiveness of bupivacaine and  
 
levobupivacaine for supraclavicular block. It was shown that equal volumes  of 
0.5%  
 
Bupivacaine.  and levoBupivacaine  produce nearly similar features .  of  
 
supraclavicular block. Bupivacaine  causes  faster motor and sensory  
 
block onset. But the  duration of  
 
postoperative analgesia is nearly the same. 
 
 
Rohit  et al conducted a study comparing 0.5% ropivacaine and 0.5%  
 
Bupivacaine in supraclavicular  brachial plexus block. They concluded that the  
 
mean onset .  time of motor blockade was nearly similar in both the groups. The 
Ropivacaine group produced a 
 
mean pain relief duration of  688 +/-.  86.78 minutes.   . In bupivacaine group, it 
was  664.37 +/- 109.mins. The  sensory and motor  
 
block.  Onset was nearly the same in both groups. 
 
 
Mithun et al performed a study comparing the effectiveness of nerve stimulator .  
vs ultrasound  
 
guided  supraclavicular .  brachial plexus block. They concluded that there was 
no  
 . significant difference between.  these groups with regard .  to demographic data,  
 
time of onset of motor and .  sensory block. A  
 
failure of 10% in ultrasound group . and 20 % in nerve stimulator .  group 
observed  
 
and  is statistically insignificant. 
 
 
Bassant mohammed et al conducted a study on the efficacy of Nalbuphine as       
 
an adjuvant to 0.25% levobupiacaine in ultrasound guided supraclaicular  
 
brachial plexus  blocks. They concluded that adding 20 mg of a Nalbuphine to 
 
 25 ml of 0.25% levobupivacaine provided prolonged duration  of  
 
sensory block with similar duration of motor block. 
 
  
Sunil chiruvella et al conducted a study comparing the various doses of  
 
Nalbuphine combined with levobupivacaine for supraclavicular brachial plexus  
 
blocks. They concluded that higher doses of  Nalbuphine in brachial plexus  
 
block fastened the onset , prolonged .  the duration of sensorimotor .             
 
blockade and analgesia, without .  any significant side effects. 
 
 
Nazir et al conducted a randomised . control trial for analysing the. Effect of 
Nalbuphine as an adjunct .  to Bupivacaine while performing supraclavicular .  
block  
 
under ultrasound . guidance. Results: When Nalbuphine is added to  
 
Bupivacaine.  as an additive, it greatly reduced the onset of . sensory  
 
and motor block . It also raised(increases) the duration of sensory and motor 
block and even the  
 duration of post operative analgesia. 
 
 
MATERIALS AND METHODOLOGY 
 
SOURCE OF DATA: 
        Patients who undergo  surgeries on the upper.  limb  done . under  
supraclavicular  brachial.  plexus block at Govt.Kilpauk medical.  college  
hospital and Govt. Royapettah .  Hospital, Chennai between a time period of  
November 2017 and April.  2018 will be assessed for .  inclusion and exclusion  
criteria . Written, informed conent is then obtained from them.  
SAMPLE SIZE CALCULATION: 
      Sample size was determined based on the 
STUDY: Effect of Nalbuphine as an adjunct to Bupivacaine for ultrasound  
                guided brachial plexus blocks. 
AUTHORISED BY: Mohammed et al 
PUBLISHED IN:  OJ Anaes 2016; vol 06(8): 1199-1203 
            This study revealed the following findings.There was  a significant  
increase in the duration  of motor block(412.559 +/- 18.63)in the Nalbuphine  
group in comparison to the control group(353.70.  +/-29.019).  Sensory duration   
was greatly increased in Nalbuphine  group(718.14 +/-21. 04) in comparison to  
control group (610.18  +/- 26. .33). But the onset time of blockade remained  
unaffected. The analgesic.  effect was significantly increased in the Nalbuphine  
group(835.18 +/- 42.45), in comparison to  to control group (708.14 +/- 54.57) 
 
DESCRIPTION: 
     The formula for detecting. sample size is given as: 
 
 
 
         
         Where n= sample size 
                     E= margin.  of error 
                     Z= margin given.  for each confidence interval 
• The confidence.  interval is estimated at 95% 
 
• Standard . deviation 59.31 
• With a Z value of 1. 96 
• The confidence interval or margin of error is estimated at +/- 16. 
      
    Taking into consideration 80 as the power of the study.,.  minimum of  
 
56 was calculated to be the sample size. 
•  In my study. I will choose 60 patients(as 10% attrition rate is taken into  
consideration). 
Group B: 30 
Group N: 30 
 
STUDY DESIGN: 
A Prospective, Randomised, double arm, double blind controlled study. 
 
 
 
INCLUSION CRITERION: 
1. Patients who undergo  elective orthopaedic forearm . fracture surgeries  
 
under . supraclavicular block. 
2. Age . between 30 to 60 years. 
3. Patients. Who weigh more than 50 kg 
4. Males . and females 
5. ASA physical status  class 1 and.  2 
6. Patients from whom valid informed consent was obtained 
EXCLUSION CRITERION: 
1. Patients who do not fulfil the inclusion criteria 
2. Patients with a history of  allergy.  or hypersensitivity to either local 
anaesthetic  or opioid group.  of drugs 
3. Any contraindication.  to peripheral nerve block 
4. Impaired ability to.  communicate(eg: confusion, poor hearing.  or 
language barrier) 
5. Patients who.  are unconscious  
6. Patients who are severely ill 
7. Pregnancy 
8. Patients with coagulation.  disorders 
9. Local infection. at the place  of injection 
10. Patients who are taking any.  sedatives or antipsychotics 
MATERIALS: 
1. Boyles apparatus 
2. Working laryngoscope with different blade sizes 
3. Other airway gadgets used in case of difficult intubation 
4. Endotracheal tubes 
5. Drugs for administering general anaesthesia 
6. Ultrasound machine 
7. 18 G iv cannula needle, tH.Ree way adapter with 10 cm extension 
8. 10 ml syringes 
9. Inj. Nalbuphine, available as ampoules(one ampoule contains 1ml, each 
ml contains 10 mg of Nalbuphine) 
10. Inj. Bupivacaine , available as vials in the concentration of 0.5%(each 
vial contains 20 ml, each ml contains 5 mg of Bupivacaine) 
METHODOLOGY: 
Patients in the above mentioned inclusion criteria will be selected and  
counselled about .  the risks  and . advantages that are involved in the study. After  
getting their valid informed  consent, patients who are  willing to be in the study  
will be enrolled and analysed. 60 patients in total will be included. Divide the  
patients into two groups 
Group B: Control group. 30 Patients .   Given  25 ml of 0.5% Bupivacaine + 1 ml  
                of.  normal saline 
Group N: Nalbuphine group. 30 patients given  25 ml of 0.5% Bupivacaine + . 1       
               ml (10 mg)of Nalbuphine  
          A thorough preoperative examination  . including history taking, physical  
examination, and   
Routine and relevant investigations were done for  all patients . Visual analogue 
pain score.  was explained to all    
candidates. Where “0” denotes no pain . “10” denotes the worst pain. An 18 G 
venflon  is 
inserted into a peripheral vein .  in the opposite forearm.  0.01-0. . 05 mg/kg of 
intravenous midazolam is given.  
Intravenous fentanyl  1 microgram/kg is given if necessary. (to.moderately 
Sedate the patient; patient is arousable on command). Basic monitoring 
consisting of  
electrocardiography, non .  invasive blood pressure and pulse.  oximetry were     
attatched.  
 
Baseline heart rate, blood.  pressure and oxygen saturation were . noted  
as pre-block.  values. Place the patient  in supine.  position . Turn the patient’s 
head to.  45 degrees to the opposite side. An ultrasound machine .  (Mindray  
M7) and a 10 MHz .  linear type probe  used. All aseptic precautions are taken. 
The skin is first cleaned and draped. Local anaesthetic infiltration of the skin is 
done.  scan the supraclavicular fossa.   
 Locate the subclavian artery , .  the 1st rib, pleura  and brachial.  plexus cluster.  
Then an echogenic 22 Gauge , 5 centimeters ,B.Braun   Needle is advanced 
from the lateral. 
 to medial direction along the long axis of ultrasound.  beams. Advance the 
needle   
towards the “corner .  pocket”.  The lower trunk frequently lies.  in this  
area (between the subclavian artery. In the medial position , first rib. below and 
the plexus  
above) . Then half the volume of the prepared.  local anaesthetic mixture  
either with.  1ml of normal  saline or 10mg of Nalbuphine was injected. Then, 
the  
needle was repositioned .  cranially towards the neural cluster so as to infiltrate  
the rest volume of the local anaesthetic just above and lateral  to the  
subclavian artery. Intraoperatively, the patient’s heart rate, mean arterial 
pressure was noted down every 5 minutes during.  the first 15 minutes.  Then it 
was noted every15  
minutes   till the end of  the surgery. If sensory and motor blockade is 
inadequate even  
after 30.  minutes of administration of .  local anaesthetic ,it is  
taken.  as an unsuccessful block. After the local anaesthetic 
administration,surgery was proceeded .  The.  onset of both motor and sensory 
blockade was noted. 
The duration of both  motor and sensory blockade and duration of analgesia was 
evaluated  by enquiring the patient in the early  
postoperative period. We routinely monitored the patientts. Side effects if any,  
are  noted.  
 
In the post operative period,  if patients started to complain .  of pain (VAS>3),  
rescue analgesia . was given as pethidine 1 mg. /kg, paracetamol  
1gram iv infusion.  or diclofenac sodium 75  mg intramuscular, until VAS<3. 
 
CRITERIA FOR 
ASSESSMENT 
Group B Group  N  
 sensory blockade Onset    
 motor.  Blockade onset    
sensory blockade 
duration 
   
 motor blockade duration    
Heart .  Rate    
Blood pressure . (mean 
arterial pressure) 
   
Respiratory rate    
Oxygen saturation    
Duration of post 
operative analgesia(time 
of first requisition of 
analgesic) 
   
 
 
METHOD OF COLLECTION OF DATA: 
    After administering the block, The evaluation of motor and sensory block  
was done every 5 minutes, till complete sensory and motor block was achieved  
or 30 minutes, whichever is earlier. To assess the sensory block, pinprick  
sensation by a 23 G hypodermic needle was used in the  
distribution of ulnar, median, musculocutaneous and radial nerves. A 3 point  
scale was used. In the 3 point scale , Zero denotes normal sensation, One 
denotes  
loss of prick sensation. Two denotes loss of sensation of touch.  
To evaluate Motor block . thumb adduction(radial nerve), opposition of thumb 
( median nerve), adduction of thumb(ulnar nerve) and elbow  
flexion(musculoctaneous nerve) is used. Similar to sensory evaluation, a 3 in  
one point scale is used . zero indicates thet motor function is normal, One 
indicates decreased motor strength, 2 indicates thet motor block is complete. 
 The time interval between .  the end of infiltration of local.  anaesthetic  and  
the complete . motor and sensory block is defined as the onset time .  for motor 
and  
sensory block respectively. Anaesthetic block on .  all the 4 nerve territories  
indicate complete sensory block. The absence of voluntary  
movements of the hand and forearm indicates complete motor  block. 
The quality of anaesthesia was  assessed at the end of the surgery. This was  
graded by:  
EXCELLENT(4): If Patient gives no complaints.  GOOD(3): Few vague  
complaints from the patient, but there is no need for any supplementation of  
drug. 
 MODERATE(2): complaint from the  
patient which necessitate need for supplemental analgesics . 
 UNSUCCESSFUL: requirement of general anaesthesia. 
Postoperatively, Patients were asked to rate their pain on a 11 point visual  
analogue scale. After discharge from the recovery room,  pain was regularly 
 assessed every 30 minutes for the first two hours, and thereafter 1 hourly till 24  
hours. The sensory and motor regression was tested every 15  
minutes until complete resolution. The time from the end of infiltration of local 
anaesthetic  till the full motor power  recovery  of the  
hand and forearm is  the duration of motor block. The duration of  
analgesia was recorded as  the time between the end of administration of the 
 local anaesthetic solution and the time of first request of rescue analgesic. 
 
 
Data Analysis 
Statistical Analysis was done by . Statistical Package for Social Sciences (SPSS 
Version 16.0) statistical.  analysis software. The values were represented in 
number (%) and mean ± standard . deviation. Acceptable statistical tests of .  
comparison were done. Continuous variables were analysed with the .  unpaired t 
test and ANOVA. Categorical variables were analysed .  with the Chi-Square 
Test and . Fisher Exact Test. Statistical significance was .  taken as P < 0.05.  
 
  
Sample Size Estimation 
Sample size was determined based on  
 
Study  
 
Effect of nalbuphine as an adjuant to bupivacaine for ultrasound guided 
supraclaicular brachial plexus blocks 
 
Authored by 
 
Mohammed et al 
 
Published in 
 
OJ Anaes 2016; Vol 06(8); 1199-1203 
 
            This study revealed the following findings.There was  a significant 
increase in the duration  
of motor block(412.559 +/- 18.63)in the Nalbuphine group in comparison to the 
control group(353.70.  +/- 
29.019).  Sensory duration  was greatly increased in Nalbuphine  
group(718.14 +/-21. 04) in comparison to control group (610.18  +/-  
26. .33). But the onset time of blockade remained unaffected. The analgesic.  
effect was significantly increased in the Nalbuphine  
group(835.18 +/- 42.45), in comparison to  to control group (708.14 +/- 54.57) 
 
 
 
 
Description: 
• The confidence level is estimated at 95% 
• with a z value of 1.96 
• the confidence interval or margin of error is estimated at +/-17 
• Assuming p% =29 and q%=71 
n = p% x q% x [z/e%] ² 
n= 29 x 71 x [1.96/17]² 
n= 28 per group  
Therefore 56 is the minimum sample size required (28 per group) for the study. 
In my study I plan to recruit a minimum of 60 subjects (30 per intervention arm) 
  
The present study was carried out at the Department of Anaesthesiology, 
Kilpauk Medical College, Chennai and Government Royapettah hospital, 
chennai, with an aim to compare the efficacy of 0.5% Bupivacaine alone vs 
0.5%Bupivacaine with.  Nalbuphine as adjuvant for ultrasound .  guided 
supraclavicular brachial plexus block 
 
A total of sixty patients were recruited and data collected was internally 
compared, tabulated, analysed and interpreted by using descriptive and 
inferential statistics based on the formulated objectives of the study. 
Study 
Groups 
Intervention Number % 
Group B 0.5% Bupivacaine alone as adjuvant for 
ultrasound guided supraclavicular brachial 
plexus block 
30 50.00 
Group N 0.5%Bupivacaine with Nalbuphine as 
adjuvant for ultrasound guided 
supraclavicular brachial plexus block 
30 50.00 
Total 60 100.00 
 
  
Age  
 
 
 
Age Groups Group B % Group N % 
≤ 20 years 2 6.67 1 3.33 
21-30 years 9 30.00 11 36.67 
31-40 years 12 40.00 12 40.00 
41-50 years 5 16.67 6 20.00 
51-60 years 2 6.67 0 0.00 
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Age Distribution Group B Group N 
Mean 34.53 33.33 
SD 10.04 7.95 
P value  
Unpaired t Test 
0.610 
 
  
On analysis of age distribution table It was evident that most of the group B 
subjects were in 31-40 years age category (40.00%) with a mean age of 34.53 
years. In group N majority were in 31-40 years age category (40.00%) with a 
mean age of 33.33 years.(p= 0.610). The data subjected to unpaired t test 
reveals the existence of statistically non-significant association between age 
distribution and intervention groups (p > 0.05) 
  
Gender  
 
 
 
Gender Status Group B % Group N % 
Male 24 80.00 23 76.67 
Female 6 20.00 7 23.33 
Total 30 100.00 30 100.00 
P value 
Chi Squared Test 
>0.999 
 
On analysis of the gender status table It is evident that most of the group B 
subjects were males (80.00%) and in group N too majority were males (76.67%) 
(p= >0.999). The data subjected to chi squared test reveals the existence of 
statistically non-significant association between gender status and intervention 
groups (p >0.05) 
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ASA Status Group B % Group N % 
ASA 1 26 86.67 26 86.67 
ASA 2 4 13.33 4 13.33 
Total 30 100.00 30 100.00 
P value 
Chi Squared Test 
>0.999 
 
On analysis of the ASA status table It is evident that most of the group B 
subjects were in ASA 1 category (86.67%) and in group N too majority were in 
ASA 1 category (86.67%) (p= >0.999). The data subjected to chi squared test 
reveals the existence of statistically non-significant association between ASA 
status and intervention groups (p >0.05) 
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Weight/Height/BMI Distribution Weight (Kgs) Height (Cms) Body mass 
index (kg/m^2) 
Group B Mean 61.37 164.73 22.78 
SD 5.37 5.45 2.00 
Group N Mean 62.53 166.10 22.73 
SD 6.20 5.17 1.97 
P value  
Unpaired t Test 
0.439 0.323 0.916 
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On analysis of weight distribution table it was evident that group B subjects had 
a mean weight of 61.37 kgs and group N subjects had a mean weight of 62.53 
kgs (p= 0.439).. In relation to height distribution group B subjects had a mean 
height of 164.73 cms and group N subjects had a mean height of 166.10 cms 
(p= 0.323)..Similarly in BMI distribution group B subjects had a mean BMI of 
22.78 and group N subjects had a mean BMI of 22.73 (p= 0.916). The data 
subjected to unpaired t test reveals the existence of statistically non-significant 
association between weight/height/BMI distribution and intervention groups (p 
> 0.05) 
  
Duration of Surgery 
 
 
 
 
Duration of Surgery Distribution 
(Mins) 
Group B Group N 
Mean 125.67 125.57 
SD 17.01 18.82 
P value  
Unpaired t Test 
0.983 
 
On analysis of duration of surgery distribution table it was evident that group B 
subjects had a mean DOS of 125.67 mins and group N subjects had a mean 
DOS of 125.57 mins (p= 0.983). The data subjected to unpaired t test reveals 
the existence of statistically non-significant association between duration of 
surgery distribution and intervention groups (p > 0.05) 
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Onset Time 
 
 
 
Onset Time Distribution Sensory Blockade 
(Mins) 
Motor Blockade 
(Mins) 
Group B Mean 14.00 20.90 
SD 1.46 2.17 
Group N Mean 14.47 21.20 
SD 1.46 1.85 
P value  
Unpaired t Test 
0.220 0.566 
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On analysis of motor blockade onset time distribution table it was evident that 
group B subjects had a mean onset time - sensory blockade of 14.00 mins and 
group N subjects had amean onset time  - sensory blockade of 14.47  mins (p= 
0.220).  
 
On analysis of motor blockade onset time distribution table it was evident that 
group B subjects had a mean onset time - motor blockade of 20.90mins and 
group N subjects had amean onset time of 21.20mins (p= 0.566).  
 
The data subjected to unpaired t test reveals the existence of statistically non-
significant association between onset time – sensory/motor distribution and 
intervention groups (p > 0.05) 
  
Duration Time 
 
 
 
Duration Time Distribution Sensory Blockade 
(Mins) 
Motor Blockade 
(Mins) 
Group B Mean 345.67 285.33 
SD 14.55 14.79 
Group N Mean 646.67 459.00 
SD 23.24 19.36 
P value  
Unpaired t Test 
<0.001 <0.001 
 
On analysis of motor blockade duration time distribution table it was evident 
that group B subjects had a mean duration time - sensory blockade of 345.67  
mins and group N subjects had a mean duration time  - sensory blockade of 
646.47  mins (p= <0.001).  
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On analysis of motor blockade duration time distribution table it was evident 
that group B subjects had a mean duration time - motor blockade of 285.33  
mins and group N subjects had amean duration time of 459.00  mins (p= 
<0.001).  
 
The data subjected to unpaired t test reveals the existence of statistically 
significant association between duration time – sensory/motor blockade 
distribution and intervention groups (p < 0.05) 
Discussion 
In our study the duration time – sensory/motor blockade distribution between 
the group B and group N was meaningfully significant. This is evident by: 
• Decreased mean duration time – sensory blockade in group B compared 
to group N (mean reduction difference of 301mins, 47% shorter). The 
same view was echoed by A study conducted by Mohammed et al on the 
effectiveness of adding Nalbuphine to Bupivacaine while performing 
supraclavicular brachial plexus blocks.  
• Decreased mean duration time – motor blockadein group B compared to 
group N (mean reduction difference of 173.67 mins, 38% shorter). The 
same view was echoed by A study conducted by Mohammed et al on the 
effectivensss of adding Nalbuphine to Bupivacaine  while performing 
supraclavicular brachial plexus blocks. 
Conclusion 
Anesthetic agent 0.5%Bupivacaine with Nalbuphinehad a longer duration of 
sensory and motor blockadecompared to 0.5% Bupivacaine alone as adjuvant 
for ultrasound guided supraclavicular brachial plexus block  
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Visual Analog Scale 6 Hrs 12 Hrs 24 Hrs 
Group B Mean 0.00 5.07 5.47 
SD 0.00 0.91 0.97 
Group N Mean 0.00 3.73 5.27 
SD 0.00 0.98 1.39 
P value 
Unpaired t Test 
>0.999 <0.001 0.521 
 
On analysis of pain score (VAS) distribution table it was evident that group B 
subjects had a mean pain score of 0.00, 5.07 and 5.47 at 6, 12 and 24 hours 
respectively. Similarly in Group N subjects had a mean pain score of 0.00, 3.73 
and 5.12 at 6, 12 and 24 hours respectively  
(6 hrs - p= >0.999). (12 hrs - p= <0.001).  (24 hrs - p= 0.521).  
 
The data subjected to unpaired t test reveals the existence of statistically non-
significant association between pain scores at 6 and 24 hours PO and 
intervention groups (p > 0.05) and reveals the existence of statistically 
significant association between pain scores at 12hours Post operatively and 
intervention groups (p < 0.05) 
Discussion 
In our study the pain score distribution between the group B and group N was 
meaningfully significant. This is evident by increased mean pain score in group 
B compared to group N (mean elevation difference of 1.33 points,26% higher). 
The same view was echoed by A study conducted by Mohammed Et al on the 
effectiveness when Nalbuphine is added as an adjunct to Bupivacaine while 
performing supraclavicular brachial plexus blocks. 
Conclusion 
There were no differences in pain scores between intervention groups during 
immediate and late postoperative period. Anesthetic agent 0.5%Bupivacaine 
with Nalbuphineproduced better medium term pain control at 12 hours 
postoperative period compared 0.5% Bupivacaine alone as adjuvant for 
ultrasound guided supraclavicular brachial plexus block.  
  
Quality of Anaesthesia 
 
 
 
Quality of Anaesthesia 
Score 
Group B % Group N % 
Score 2 12 40.00 1 3.33 
Score 3 15 50.00 8 26.67 
Score 4 3 10.00 21 70.00 
Total 30 100.00 30 100.00 
P value 
Chi Squared Test 
0.071 
On analysis of quality of anaesthesia score distribution table it was evident that  
majority of group B subjects had QAS of score 3 (50,00%) and majority of  
group N subjects had QAS of  score 4 (70,00%) (p= 0.071). The data subjected  
to chi squared test reveals the existence of statistically non-significant  
association between quality of anaesthesia scores and intervention groups (p > 
0.05)  
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Opioid Requirement in 
24 hrs (Doses) 
Group B % Group N % 
One 2 6.67 24 80.00 
Two 7 23.33 6 20.00 
Three 16 53.33 0 0.00 
Four 5 16.67 0 0.00 
Total 30 100.00 30 100.00 
P value 
Chi Squared Test 
<0.001 
 
On analysis of opioid requirement for 24 hours distribution table it was evident 
that majority of group B subjects were given three doses of opioid (53,33%) and 
majority of group N subjects were given one dose of opioid (80,00%) (p= 
<0.001). The data subjected to chi squared test reveals the existence of 
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statistically significant association between opioid requirement for 24 hours and 
intervention groups (p < 0.05)  
Discussion 
In our study the opioid  requirement for 24 hours distribution between the group 
B and group N was meaningfully significant. This is evident by increased 
opioid requirement for 24 hours in group B compared to group N (mean 
increased difference of 73.33 points at one dose level, 92% higher). The same 
view was echoed by The study conducted by Mohammed et al on the 
effectiveness of  Nalbuphine when added to Bupivacaine as adjunct while 
performing supraclavicular brachial plexus blocks. 
Conclusion 
Anesthetic agent 0.5%Bupivacaine with Nalbuphine produced better pain 
management compared to 0.5% Bupivacaine as adjuvant for ultrasound guided 
supraclavicular brachial plexus block 
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Pulse Rate Distribution Group B Group N P value  
Unpaired t Test 
Mean SD Mean SD 
Baseline 79.17 7.71 80.43 6.81 0.503 
5 M 79.53 6.54 77.37 7.52 0.238 
10 M 82.43 6.93 80.37 8.14 0.294 
15 M 83.30 6.25 77.17 7.36 0.456 
20 M 82.80 5.68 80.07 7.70 0.123 
30 M 83.20 5.07 76.90 7.91 0.582 
45 M 84.00 6.52 78.27 10.18 0.712 
1 HR 80.70 7.03 78.63 7.75 0.284 
2 HR 86.03 7.24 76.50 6.70 0.445 
3 HR 79.40 7.70 79.50 8.06 0.961 
4 HR 85.03 6.54 81.20 7.12 0.682 
5 HR 85.20 8.09 81.57 6.00 0.065 
6 HR 83.07 5.00 80.00 8.15 0.084 
8 HR 83.37 4.67 80.37 7.25 0.062 
12 HR 83.27 6.64 82.13 7.92 0.550 
16 HR 81.37 6.19 83.83 6.21 0.129 
24 HR 87.57 8.32 90.20 8.91 0.242 
On analysis of pulse rate distribution table it was evident that group B subject  
had a mean overall PR of 82.91 bpm and group N subjects had a mean overall  
PR of 80.94 bpm (p= 0.216). The data subjected to unpaired t test reveals the  
existence of statistically non-significant association betweenpulse rate and  
intervention groups (p > 0.05)  
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 Mean Arterial Pressure 
Distribution 
Group B Group N P value  
Unpaired t Test 
Mean SD Mean SD 
Baseline 84.73 5.58 87.73 7.60 0.087 
5 Minutes 86.13 7.03 88.27 8.21 0.284 
10 Minutes 87.43 6.95 87.67 8.51 0.908 
15 Minutes 87.23 6.80 88.33 8.47 0.581 
20 Minutes 85.37 6.24 87.43 8.84 0.300 
30 Minutes 83.33 16.11 87.10 7.59 0.251 
45 Minutes 86.93 7.14 86.10 7.25 0.655 
1 Hour 85.83 6.33 85.27 6.82 0.740 
2 Hours 84.63 7.56 111.17 140.70 0.307 
3 Hours 85.37 6.57 86.73 7.47 0.455 
4 Hours 85.43 6.33 86.93 6.91 0.384 
5 Hours 85.93 7.72 86.43 6.33 0.785 
6 Hours 84.00 15.40 88.03 7.34 0.200 
8 Hours 85.93 6.03 84.23 15.26 0.573 
12 Hours 86.17 6.11 85.53 8.55 0.743 
16 Hours 85.83 5.83 84.80 7.81 0.564 
24 Hours 83.67 5.82 87.20 6.12 0.026 
Overall 85.53 4.99 88.17 9.78 0.192 
 
On analysis of mean arterial pressure distribution table it was evident that group 
B subject had a mean overall MAP of 85.53 mm Hg and group N subjects had a 
mean overall MAP of 88.17 mm Hg (p= 0.192). The data subjected to unpaired 
t test reveals the existence of statistically non-significant association between 
mean arterial pressure and intervention groups (p > 0.05)  
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SPO2 Distribution Group B Group N P value  
Unpaired t Test 
Mean SD Mean SD 
Baseline 99.20 0.85 99.47 0.63 0.171 
5 Minutes 98.97 2.37 97.33 5.70 0.152 
10 Minutes 98.93 2.89 99.47 0.63 0.327 
15 Minutes 98.80 2.54 99.37 0.72 0.244 
20 Minutes 98.77 2.24 99.17 0.87 0.366 
30 Minutes 98.50 2.45 99.13 0.78 0.182 
45 Minutes 98.63 2.40 98.70 1.02 0.889 
1 Hour 98.83 0.83 98.90 1.12 0.795 
2 Hours 98.97 0.85 98.80 1.00 0.489 
3 Hours 98.87 0.97 98.83 0.91 0.892 
4 Hours 99.10 0.92 98.70 0.99 0.111 
5 Hours 99.20 0.81 99.07 0.83 0.530 
6 Hours 99.20 0.92 98.77 1.01 0.088 
8 Hours 99.10 0.88 99.10 0.71 >0.999 
12 Hours 99.33 0.76 99.13 0.97 0.378 
16 Hours 99.27 0.78 99.07 0.94 0.376 
24 Hours 99.27 0.91 98.97 0.89 0.201 
 
On analysis of SPO2 distribution table it was evident that group B subject had a 
mean overall SPO2 of 99.00% and group N subjects had a mean overall SPO2 
of 98.94% (p= 0.808). The data subjected to unpaired t test reveals the existence 
of statistically non-significant association betweenSPO2and intervention groups 
(p > 0.05)  
 Overall Conclusion 
Anesthetic agent 0.5%Bupivacaine with Nalbuphine in comparisin to 
0.5%Bupivacaine alone as adjuvant for ultrasound guided supraclavicular 
brachial plexus block: 
• Equivocal duration of surgery 
• Equivocal sensory blockade onset time 
• Equivocal motor blockade onset time 
• Longer duration of sensory blockade 
• Longer duration of motor blockade 
• Equivocal immediate postoperative pain scores 
• Lower postoperative pain scores at 12 hours 
• Equivocal  Quality of anaesthesia  
• Lower opioid requirement  
• Better immediate and midterm postoperative pain management 
• Equivocal hemodynamic stability 
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PROFORMA 
“A STUDY ON THE EFFECT OF NALBUPHINE AS AN ADJUVANT  
TO BUPIVACAINE FOR ULTRASOUND GUIDED  
SUPRACLAVICULAR  BRACHIAL PLEXUS NERVE  BLOCK” 
 
 
Name:              
 Age/Gender:                 
 IP Number: 
Height:         cm       
 Weight:         kg       
 BMI: 
Date of surgery: 
ASA Physical status:                   
 Co morbidity:        
 Drug history: 
Group(Tick any one) 
Group B : 25 ml Bupivacine 0.5% and 1 ml normal saline  (control group). 
Group N : 25 ml Bupivacaine 0.5% plus 10 mg Nalbuphine (test group) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASSESSMENT 
CRITERIA 
Group B Group  N  
Onset of sensory 
blockade 
   
Onset of motor blockade    
Duration of sensory 
blockade 
   
Duration of motor 
blockade 
   
Heart rate    
Blood pressure(mean 
arterial pressure) 
   
Respiratory rate    
Oxygen saturation    
Duration of post 
operative analgesia(time 
of first requisition of 
analgesic) 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FORM 
  
STUDY: “A STUDY ON THE EFFECT OF NALBUPHINE AS AN  
ADJUVANT TO BUPIVACAINE FOR ULTRASOUND GUIDED 
 SUPRACLAVICULAR BRACHIAL PLEXUS NERVE BLOCK”. 
 
 
STUDY CENTRE:  GOVT. KILPAUK MEDICAL COLLEGE HOSPITAL & 
GOVT ROYAPETTAH     HOSPITAL, CHENNAI. 
PATIENT’S NAME: 
 
PATIENT’S AGE: 
 
I.P NO            : 
 
 Patient may check (  ) these boxes 
 
I confirm that I understood the purpose of the procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction 
 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
need not my permission to look at my health records, both in respect of 
the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under 
the law. 
  
I agree not to restrict the use of any data or results that arise from the 
study.I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully co operate with the study 
team and to immediately inform the study staff if I suffer from any 
deterioration in my health or well being or any unexpected or unusual 
symptoms. 
 
I hereby consent to participate in this study. 
 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including hematological, biochemical, radiological tests. 
 
 
 
 
Signature / thumb impression:  
 
                             
Patient’s name and address:                                          place:                                  
date: 
 
 
Signature of the investigator: 
Study investigator’s name:                                             place:                     date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   PARTICIPANTS INFORMATION SHEET 
 
Investigator   :  
 
Name of the participant :  
 
Title:   ” A STUDY ON THE EFFECT OF NALBUPHINE AS AN 
ADJUVANT TO BUPIVACAINE FOR ULTRASOUND GUIDED 
 SUPRACLAVICULAR BRACHIAL PLEXUS NERVE BLOCK”. 
 
You are invited to take part in this research study. We have got approval 
from the IEC. You are asked to participate because you satisfy the 
eligibility criteria. 
What is the purpose of this research? 
  In this study, efficacy of Nalbuphine as adjuvant to Bupivacaine 
for supraclavicular block will be evaluated so that the patient will have 
increased duration of postoperative analgesia without much effect on the onset 
of sensory or motor blockade. 
BENEFITS: 
         This study will help us in determining the effect of Nalbuphine as an 
adjuvant to Bupivacaine for supraclavicular brachial plexus 
blocks.Nalbuphine causes better postoperative analgesia without much 
affecting the onset of motor and sensory block.  
   
DISCOMFORTS AND RISKS: 
 Nalbuphine may also cause nausea, vomting, pruritus and dizziness in 
some patients. 
CONFIDENTIALITY: 
Patients who participated in the study and their details will be maintained 
confidentially and at any cost, those details will not be let out 
RIGHT TO WITHDRAW : 
Patients  will not be forced to complete the study. At any cost, in such 
circumstances the treatment  will not be compromised. 
 
Date :      Signature of the investigator:  
 
Place : 
Signature/Thumb 
impressionof  the 
participant 
 
சுய ஒப்புதல் படிவம் 
 
ஆய்வு செய்யப்படும் தலைப்பு 
கீழ்ப்பாக்கம் மற்றும் ராயப்பபட்டா அரசு பபாது மருத்துவமனையில் பமல் மூட்டு அறுனவ 
சிகிச்னசயில் கமுத்துப்பட்னட எலும்புக்கு பமல்நினையாை நரம்புகனை சுற்றியுள்ை 
பகுதியில் nalbuphine+bupivacaine  ஆகியவற்றின் வைி நிவாரணி பண்புகைின் ஒப்பிட்டு ஆய்வு. 
 
ஆராய்ச்சி நினையம்: மயக்கவியல் மருத்துவத் துனற, 
கீழ்ப்பாக்கம் மருத்துவக்கல்லூரி மற்றும் ராயப்பபட் 
அரசு பபாது மருத்துவமனை, 
பசன்னை  
 
பங்கு சபறுபவரின் சபயர்:        உறவு முலற: 
பங்கு சபறுபவரின் எண்: 
பங்கு சபறுபவர் இதலை (√) குறிக்கவும் 
பமபை குறிப்பிட்டுள்ை மருத்துவ ஆய்வின் விவரங்கள் எைக்கு விைக்கப்பட்டது. 
என்னுனடய சந்பதகங்கனை பகட்கவும் அதற்காை தகுந்த விைக்கங்கனைப் 
பபறவும் வாய்ப்பைிக்கப்பட்டது.  
நான் இவ்வாய்வில் தன்ைிச்னசயாகத்தான் பங்பகற்கிபறன். எந்தக் 
காரணத்திைாபைா எந்தக் கட்டத்திலும் எந்த சட்ட சிக்கலுக்கும் உட்படாமல் நான் 
இவ்வாய்வில் இருந்து விைகிக் பகாள்ைைாம் என்றும் அறிந்து பகாண்படன். 
இந்த ஆய்வு சம்மந்தமாகவும், பமலும் இது சார்ந்த ஆய்வு 
பமற்பகாள்ளும்பபாதும், இந்த ஆய்வில் பங்குபபறும் மருத்துவர் என்னுனடய 
மருத்துவ அறிக்னககனைப் பார்ப்பதற்கு என் அனுமதி பதனவயில்னை எை 
அறிந்துபகாள்கிபறன். நான் ஆய்வில் இருந்து விைகிக் பகாண்டாலும் இது 
பபாருந்தும் எை அறிகிபறன். 
இந்த ஆய்வின் மூைம் கினடக்கும் தகவல்கனையும், பரிபசாதனை 
முடிவுகனையும் மற்றும் சிகிச்னச பதாடர்பாை தகவல்கனையும் மருத்துவர் 
பமற்பகாள்ளும் ஆய்வில் பயன்படுத்திக் பகாள்ைவும், அனதப் பிரசுரிக்கவும் என் 
முழு மைதுடன் சம்மதிக்கிபறன். 
இந்த ஆய்வில் பங்கு பகாள்ை ஒப்புக்பகாள்கிபறன். எைக்குக் 
பகாடுக்கப்பட்ட அறிவுனரகைின் படி நடந்துபகாள்வதுடன், இந்த ஆய்னவ 
பமற்பகாள்ளும் மருத்துவ அணிக்கு உண்னமயுடன் இருப்பபன் என்றும் 
உறுதியைிக்கிபறன். என் உடல் நைம் பாதிக்கப்பட்டாபைா அல்ைது எதிர்பாராத 
வழக்கத்திற்கு மாறாக பநாய்க்குறி பதன்பட்டாபைா உடபை அனத மருத்துவ 
அணியிடம் பதரிவிப்பபன் எை உறுதி அைிக்கிபறன். 
இந்த ஆய்வில் எைக்கு மருத்துவப் பரிபசாதனை, பமல் மூட்டு அறுனவ 
சிகிச்னசயில் கமுத்துப்பட்னட எலும்புக்கு பமல்நினையாை நரம்புகனை 
சுற்றியுள்ை பகுதியில் nalbuphine+bupivacaine ஆகியவற்றின் வைி நிவாரணி 
பண்புகைின் ஒப்பிட்டு ஆய்வுகுறித்து ஆராய்ச்சி  பசய்து பகாள்ை நான் முழு 
மைதுடன் சம்மதிக்கிபறன். 
 
பங்பகற்பவரின் னகபயாப்பம் ....................................................................  இடம் .............................................. 
பததி ........................ 
கட்னடவிரல் பரனக: 
 
பங்பகற்பவரின் பபயர் மற்றும் விைாசம் 
................................................................................................................................................... 
ஆய்வாைரின் னகபயாப்பம் .......................................................................... இடம் 
.................................................பததி ..................... 
ஆய்வாைரின் பபயர் .......................................................................................... 
  
ஆராய்ச்சி தகவல் தாள் 
 
கீழ்ப்பாக்கம் மற்றும் ராயப்பபட்டா அரசு பபாது பமல் மூட்டு அறுனவ சிகிச்னசயில் 
கமுத்துப்பட்னட எலும்புக்கு பமல்நினையாை நரம்புகனை சுற்றியுள்ை பகுதியில் 
nalbuphine+bupivacaine நிவாரணி பண்புகைின் ஒப்பிட்டு ஆய்வு பசய்ய உள்பைாம். 
நீங்கள் இந்த ஆராய்ச்சியில் பங்பகற்க நாங்கள் விரும்புகிபறாம். இந்த 
ஆராய்ச்சியில் பங்பகற்பதால் தங்கைது பநாயின் ஆய்வறிக்னகபயா அல்ைது 
சிகிச்னசபயா பாதிக்கப்படாது என்பனதயும் பதரிவித்துக் பகாள்கிபறாம். 
இந்த ஆராய்ச்சியின் முடிவுகனை அல்ைது கருத்துகனை பவைியிடும் பபாபதா 
அல்ைது ஆராய்ச்சியின் பபாபதா தங்கைது பபயனரபயா அல்ைது அனடயாைங்கனைபயா 
பவைியிடமாட்படாம் என்பனதயும் பதரிவித்துக் பகாள்கிபறாம். 
இந்த ஆராய்ச்சியில் பங்பகற்பது தங்களுனடய விருப்பத்தின் பபரில் தான் 
இருக்கிறது. பமலும் நீங்கள் எந்பநரமும் இந்த ஆராய்ச்சியில் இருந்து பின்வாங்கைாம் 
என்பனதயும் பதரிவித்துக்பகாள்கிபறாம். 
இந்த சிறப்புப் பரிபசாதனைகைின் முடிவுகனை ஆராய்ச்சியின் பபாபதா அல்ைது 
ஆராய்ச்சியின் முடிவின் பபாபதா தங்களுக்கு அறிவிப்பபாம் என்பனதயும் 
பதரிவித்துக்பகாள்கிபறாம்.  
 
 
ஆராய்ச்சியாைர் னகபயாப்பம்                  பங்பகற்பாைர் னகபயாப்பம் 
 
பததி: 
 
 
 
S.NO 
Name 
Age Sex 
ASA  
status Wt in 
Kg 
Height 
in Cm 
Body 
mass 
index 
in 
kg/m^2 
Duration 
of 
Surgery 
(Minutes) 
Onset Time 
(Minutes) 
Duration(Minutes) 
        sensory 
blockade 
Motor 
blockade 
Sensory 
blockade 
1 kathir  28 male 1 61 161 23.82 125 14 20 340 
2 Pandi 25 male 1 56 165 20.57 140 15 23 350 
3 jagadeesh 22 male 1 54 158 21.68 155 16 18 330 
4 ravi 44 male 2 68 163 25.66 100 12 19 370 
5 santhakumari 42 male 1 59 169 21.93 110 15 21 340 
6 lawrence 28 male 1 64 174 22.14 95 13 20 360 
7 karthick 17 male 1 52 162 19.84 125 14 22 350 
8 
shakul 
ahmed 32 male 1 63 155 26.25 130 16 23 330 
9 thulasi 40 female 2 65 167 23.38 145 12 19 340 
10 lakshmi 38 female 1 61 174 20.19 120 13 18 340 
11 murugayan 40 male 1 64 169 22.45 135 15 23 350 
12 ranjithkumar 30 male 1 65 159 25.79 145 12 20 330 
13 ramya 26 female 1 57 168 20.21 150 14 21 320 
14 jeeva 32 female 1 61 171 20.89 135 14 18 350 
15 mani 24 male 1 62 168 21.98 125 15 19 340 
16 vignesh 19 male 1 46 159 18.25 110 16 20 370 
17 mohan 35 male 1 64 163 25.29 90 13 24 360 
18 praveen 36 male 1 63 170 21.79 120 12 23 350 
19 chinnapa 33 male 1 64 168 22.69 130 11 20 370 
20 tirupathi 34 male 1 65 163 24.52 125 14 21 360 
21 kalaiseli 34 female 1 56 152 24.2 130 16 24 350 
22 muthukumar 33 male 1 1 68 163 25.62 145 14 20 360 
23 harish 25 male 1 60 167 21.53 135 15 23 330 
24 kumar  45 male 2 68 167 24.43 140 16 24 360 
25 poongodi  28 female 1 54 154 22.78 120 13 18 340 
26 kumaravel 60 male 1 60 165 22 130 14 18 330 
27 kannadasn 56 male 1 65 167 23.32 140 12 18 320 
28 kanniyappan 45 male 2 60 166 21.79 120 14 23 360 
29 manish 40 male 1 66 167 23.71 105 16 24 330 
30 lalu 45 male 1 70 168 24.82 95 14 23 340 
            
            
            
            
            
            
            
            
            
            
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
